RE: SRA 737 milestone payments16 May 2022 08:11
Bluenose, have a look at the following GSK press release ref planned purchase of Sierra
https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-to-acquire-late-stage-biopharmaceutical-company-sierra-oncology-for-19bn/
You will see the following para:
“Sierra Oncology is a late-stage biopharmaceutical company based in San Mateo, California, on a mission to deliver targeted therapies that treat rare forms of cancer. In addition to momelotinib, the pipeline consists of two assets in phase I SRA515 and SRA737. SRA515 is a selective bromodomain-containing protein 4 (BRD4) bromodomain and extra-terminal domain (BET) inhibitor with a novel bivalent binding mode that inhibits both protein bromodomains, and SRA737 is a novel checkpoint kinase 1 (CHK1) inhibitor.”
Note they refer to SRA737 as an asset.
Ask yourself this question? What is an asset?
According to the Oxford dictionary “an item of property owned by a person or company, regarded as having value and available to meet debts, commitments, or legacies.”
They have already confirmed it has value, so what do you think they will do with it?